Bayer AG (BAYN) - Medical Equipment - Deals and Alliances Profile

Bayer AG (BAYN) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME40270D
  • |
  • Pages: 105
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women's health, cancer, hematology, ophthalmology and other indications. The company's product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter-OTC) products, seeds, crop protection solutions and nonagricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG (BAYN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Bayer AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Bayer AG, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Bayer AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Bayer AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 10

Bayer AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Bayer AG, Medical Equipment, Deal Details 13

Private Equity 13

Bayer to Raise USD3.69 Billion in Private Placement of Shares 13

Partnerships 15

Bayer Enters into Licensing Agreement with DelSiTech 15

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 16

TissUse Enters into Co-development Agreement with Bayer 17

Icagen Enters into Agreement with Bayer 18

Bayer Enters into Co-Development Agreement with Leica Biosystems 19

T2 Biosystems Enters into R&D Agreement with Bayer 20

Genedata Enters into Co-Development Agreement with Bayer Pharma 21

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 22

Ventana Extends Co-Development Agreement With Bayer Pharma 23

Bayer Yakuhin Enters Into Distribution Agreement With Femasys For FemVue Saline-Air Device 24

Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 25

Equity Offering 26

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 26

Debt Offering 27

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 27

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 28

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 29

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 30

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 31

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 32

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 33

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 34

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 35

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 36

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 37

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 38

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 39

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 41

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 43

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 44

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 45

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 46

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 47

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 48

Asset Transactions 49

Bayer May Sell Radiology Business 49

Panasonic Healthcare Acquires Diabetes Care Business from Bayer for USD1.15 Billion 50

Boston Scientific Acquires Vascular Catheter Business of Bayer for USD414 Million 51

Polymer Technology Systems Acquires A1CNow From Bayer Diabetes Care 52

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 53

Acquisition 54

Bayer May Acquire Sirtex Medical 54

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 55

Bayer AG-Key Competitors 57

Bayer AG-Key Employees 58

Bayer AG-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Joint Venture 68

Recent Developments 69

Strategy And Business Planning 69

Mar 06, 2018: Travelers Partners with Cedars-Sinai, Samsung Electronics America, Bayer and appliedVR to Test Digital Tools in Treatment of Acute Orthopaedic Injuries 69

Financial Announcements 70

May 03, 2018: Bayer: Operational business held back by currency effects-Major progress with Monsanto acquisition 70

Oct 26, 2017: Bayer: Sales and earnings increased 74

Apr 27, 2017: Strong start to the year for Bayer 79

Corporate Communications 82

Sep 27, 2018: Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas 82

Sep 13, 2018: Bayer appointed Stefan Oelrich to Board of Management 83

May 07, 2018: Bayer announces Executive Leadership Team for new Crop Science division 85

Nov 15, 2017: Heiko Schipper to join Bayer Board of Management and head Consumer Health Division 87

Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 88

Oct 19, 2017: Bayer Appoints Jennifer Brendel to Vice President, Head of U.S. Consumer Health Communications 89

Sep 22, 2017: Bayer Appoints Dr. Sharon James Head of Global Innovation & Development for Consumer Health 90

Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 91

Sep 07, 2017: Bayer again listed in the Dow Jones Sustainability World Index 92

Jun 05, 2017: Bayer Expands Oncology Organization with Two New Leadership Team Appointments 93

May 02, 2017: Bayer Appoints Bhavesh Ashar to Lead U.S. Oncology Business 94

Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 95

Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region 96

Legal and Regulatory 97

Aug 22, 2017: Bayer will continue to work constructively with the European Commission 97

Government and Public Interest 98

Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 98

Feb 22, 2017: Another record year for Bayer-good progress with the acquisition of Monsanto 99

Product News 103

Dec 04, 2017: NUST MISIS Students Develop an App for Patients with Bronchiectasis 103

Other Significant Developments 104

Mar 27, 2018: Bayer partners with Plug and Play To Address the Rapid Changes in Healthcare 104

Appendix 105

Methodology 105

About GlobalData 105

Contact Us 105

Disclaimer 105

List of Figures

Bayer AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Bayer AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Bayer AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Bayer AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Bayer AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Bayer AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 8

Bayer AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Bayer AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

List of Tables

Bayer AG, Medical Equipment, Key Facts, 2017 2

Bayer AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Bayer AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Bayer AG, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Bayer AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Bayer AG, Deals By Market, 2012 to YTD 2018 10

Bayer AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Bayer to Raise USD3.69 Billion in Private Placement of Shares 13

Bayer Enters into Licensing Agreement with DelSiTech 15

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 16

TissUse Enters into Co-development Agreement with Bayer 17

Icagen Enters into Agreement with Bayer 18

Bayer Enters into Co-Development Agreement with Leica Biosystems 19

T2 Biosystems Enters into R&D Agreement with Bayer 20

Genedata Enters into Co-Development Agreement with Bayer Pharma 21

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 22

Ventana Extends Co-Development Agreement With Bayer Pharma 23

Bayer Yakuhin Enters Into Distribution Agreement With Femasys For FemVue Saline-Air Device 24

Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 25

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 26

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 27

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 28

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 29

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 30

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 31

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 32

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 33

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 34

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 35

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 36

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 37

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 38

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 39

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 41

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 43

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 44

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 45

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 46

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 47

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 48

Bayer May Sell Radiology Business 49

Panasonic Healthcare Acquires Diabetes Care Business from Bayer for USD1.15 Billion 50

Boston Scientific Acquires Vascular Catheter Business of Bayer for USD414 Million 51

Polymer Technology Systems Acquires A1CNow From Bayer Diabetes Care 52

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 53

Bayer May Acquire Sirtex Medical 54

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 55

Bayer AG, Key Competitors 57

Bayer AG, Key Employees 58

Bayer AG, Subsidiaries 59

Bayer AG, Joint Venture 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bayer AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com